CytoSorbents Reports on Successful DIVI 2013 Conference

CytoSorbents Reports on Successful DIVI 2013 Conference 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 12/16/13 --  CytoSorbents
Corporation (OTCBB: CTSO), a critical care focused company
commercializing its European Union approved CytoSorb(R) blood filter
to treat life-threatening illnesses in the intensive care unit,
reports on its recent activities at the DIVI 2013 Congress in
Leipzig, Germany. 
DIVI, or the German Interdisciplinary Coalition for Intensive Care
and Emergency Medicine, is one of the premier German medical
societies dedicated to improving outcomes in patients in the
intensive care unit and emergency room. Its members primarily consist
of critical care and emergency medicine physicians, nurses, and other
healthcare providers of all levels of experience throughout the
region. This month, the DIVI 2013 Congress attracted approximately
3,000 attendees from the region. 
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, stated,
"The DIVI Annual Congress is a key event for us because it gives
invaluable access to thousands of critical care physicians and
nurses, both senior and junior, in our core direct sales markets of
Germany, Austria, and Switzerland. This is a perfect fit as we
continue to drive awareness and usage of CytoSorb(R) amongst these
providers deep within each critical care department. Interestingly,
the conference is conducted exclusively in German, making it easy and
comfortable for all native German-speaking attendees to fully
understand the scientific content. Also of note, walking through the
exhibition hall, CytoSorbents continues to stand out as one of the
only true innovations in the treatment of patients in the ICU."  
Dr. Chan continued, "This year, in addition to exhibiting, we had a
very ambitious agenda. Prior to the start of the Congress, we hosted
our first ever CytoSorb(R) user's meeting, where treatment pioneers
from all over Germany and Austria gathered to share their clinical
experiences using CytoSorb(R) in fifteen presentations throughout the
day and during dinner at night. The presented case reports and case
series encompassed hundreds of treatments ranging from the treatment
of severe sepsis and septic shock, rhabdomyolysis, liver disease,
necrotizing fasciitis, and others, to the use of CytoSorb(R) both
intra-operatively and post-operatively in cardiac surgery, and with
ECMO (extracorporeal membrane oxygenation) to stabilize a patient in
air transport." 
"There was an energy and excitement level amongst the user's group
that is difficult to explain," Dr. Christian Steiner, Vice President
of Sales and Marketing, remarked. "A repeated message throughout the
meeting was that the doctors could see the therapy 'turning the
patient around' with an immediate positive effect on patient
stability in many cases, as seen by a reduction in vasopressor or
oxygen usage for example. This could often be matched with a
significant reduction in cytokines and other inflammatory markers. To
hear this, and to see the data that CytoSorb(R) was not just a 'black
box', but was working to help physicians regain control of their
patients across a wide range of applications, was very exciting. In
addition, we continue to receive common feedback that CytoSorb(R) is
easy and safe to use, without complications. Most of the presenters
plan to submit their data for publication in the near future, and
because of this, the public availability of these presentations is
limited." 
In addition to the user's meeting, CytoSorbents also sponsored a 90
minute symposium entitled, "SIRS and Sepsis -- A New Therapy Approach
with CytoSorb(R)". The event featured presentations from: 


 
--  Dr. Axel Nierhaus - University of Hamburg-Eppendorf Hospital: "The
    Excessive Immune Response - The Root of All Evil?"
--  Prof. Dr. Michael Quintel - University Goettingen Hospital:
    "CytoSorb(R): A New Therapeutic Approach for Severe SIRS - An
    Overview"
--  Prof. Dr. Karl Traeger - University of Ulm Hospital: "Clinical
    Experience with the Use of CytoSorb(R) Therapy in Cardiovascular
    Surgery"

  
In addition, Prof. Dr. Frank Brunkhorst from the University of Jena
Hospital, announced the initial development of the SepNet CytoSorb(R)
Registry. The University of Jena is one of the leading institutions
in sepsis and critical care research in the world, and the home of
the German Sepsis Society and the Sepsis Trials Network (SepNet) -- a
government funded consortium of physicians and hospitals throughout
Germany that conduct clinical trials in sepsis. This registry will
become a central repository of clinical data from usage of
CytoSorb(R) all over the world, in many different applications, not
just sepsis. 
Dr. Chan commented, "Given the early morning start and specific focus
of the symposium on CytoSorb(R), we expected approximately 50-75
people to attend, but were pleasantly surprised to have nearly 120
people attending the session. The presentations were excellent,
covering our two leading indications for CytoSorb(R) -- sepsis and
cardiac surgery. The feedback mirrored our exhibit booth traffic,
where the level of interest in CytoSorb(R) from both physicians and
nurses was fantastic." 
Photos from the user's meeting, company sponsored symposium, and
conference can be viewed starting later today on our Twitter feed
(https://twitter.com/CytoSorbents) and on our Facebook page at:
https://www.facebook.com/#!/cytosorbents  
About DIVI 
The DIVI (Deutsche Interdisziplinaere Vereinigung fuer Intensiv- und
Notfallmedizin) Society was founded in 1977 to foster the cooperation
and exchange of knowledge and information between physicians, nurses
and other healthcare professionals who specialize in intensive care
and emergency medicine. The goal of this premier organization is to
foster a collaborative environment where advances in medicine and
patient care can be shared, to benefit the welfare of patients.
http://www.divi2013.de/index.php?id=37 
About CytoSorbents Corporation  
CytoSorbents is a critical care focused therapeutic device company
using blood purification to modulate inflammation - with the goal of
preventing or treating multiple organ failure in life-threatening
illnesses. Organ failure is the cause of nearly half of all deaths in
the intensive care unit, with little to improve clinical outcome.
CytoSorb(R), the Company's flagship product, is approved in the
European Union as a safe and effective extracorporeal cytokine
filter, designed to reduce the "cytokine storm" that could otherwise
cause massive inflammation, organ failure and death in common
critical illnesses such as sepsis, burn injury, trauma, lung injury,
and pancreatitis. These are conditions where the mortality is
extremely high, yet no effective treatments exist. CytoSorbents'
purification technologies are based on biocompatible, highly porous
polymer beads that can actively remove toxic substances from blood
and other bodily fluids by pore capture and surface adsorption.
CytoSorbents has numerous products under development based upon this
unique blood purification technology, protected by 32 issued US
patents and multiple applications pending, including HemoDefend(TM),
ContrastSorb, DrugSorb, and others. Additional information is
available for download on the Company's website:
http://www.cytosorbents.com 
Forward-Looking Statements 
This press release includes forward-looking statements intended to
qualify for the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Forward-looking statements
i
n this press release are not promises or guarantees and are subject
to risks and uncertainties that could cause our actual results to
differ materially from those anticipated. These statements are based
on management's current expectations and assumptions and are
naturally subject to uncertainty and changes in circumstances. We
caution you not to place undue reliance upon any such forward-looking
statements. Actual results may differ materially from those expressed
or implied by the statements herein. Risk factors are detailed in the
Company's Form 10-K filed with the SEC on April 3, 2013, which is
available at http://www.sec.gov. 
Company Contact: 
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer 
(732) 329-8885 ext. *823
pchan@cytosorbents.com 
Investor Contact: 
Alliance Advisors, LLC
Alan Sheinwald 
(914) 669-0222
asheinwald@allianceadvisors.net 
Valter Pinto 
(914) 669-0222 x201
valter@allianceadvisors.net 
Media Contact: 
JQA Partners
Jules Abraham 
(917) 885-7378
jabraham@jqapartners.com